Search

Your search keyword '"Ting, Lai-Lei"' showing total 162 results
Start Over Author "Ting, Lai-Lei"
162 results on '"Ting, Lai-Lei"'

4. Development and evaluation of ultrasound image tracking technology based on Mask R-CNN applied to respiratory motion compensation system

Author

Ting, Lai-Lei, primary, Guo, Ming-Lu, additional, Liao, Ai-Ho, additional, Cheng, Sen-Ting, additional, Yu, Hsiao-Wei, additional, Ramanathan, Subramaninan, additional, Zhou, Hong, additional, Boominathan, Catherin Meena, additional, Jeng, Shiu-Chen, additional, Chiou, Jeng-Fong, additional, Kuo, Chia-Chun, additional, and Chuang, Ho-Chiao, additional

Published
2023
Full Text
View/download PDF

7. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression

Author

Ho, Chin-Beng, primary, Tsai, Jo-Ting, additional, Chen, Chun-You, additional, Shiah, Her-Shyong, additional, Chen, Hsuan-Yu, additional, Ting, Lai-Lei, additional, Kuo, Chia-Chun, additional, Lai, I-Chun, additional, Lai, Hsin-Yi, additional, Chung, Chi-Li, additional, Lee, Kai-Ling, additional, Tzeng, Huey-En, additional, Lee, Kuen-Haur, additional, Lee, Hsin-Lun, additional, Chen, Shang-Wen, additional, and Chiou, Jeng-Fong, additional

Published
2023
Full Text
View/download PDF

10. Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients with Head and Neck Cancer

Author

Lin, Kuan-Chou, primary, Ting, Lai-Lei, additional, Chang, Chia-Lun, additional, Lu, Long-Sheng, additional, Lee, Hsin-Lun, additional, Hsu, Fang-Chi, additional, Chiou, Jeng-Fong, additional, Wang, Peng-Yuan, additional, Burnouf, Thierry, additional, Ho, Dennis Chun-Yu, additional, Yang, Kai-Chiang, additional, Chen, Chang-Yu, additional, Chen, Chu-Huang, additional, Wu, Ching-Zong, additional, and Chen, Yin-Ju, additional

Published
2021
Full Text
View/download PDF

19. Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer

Author

Lee, Hsin-Lun, primary, Chiou, Jeng-Fong, additional, Wang, Peng-Yuan, additional, Lu, Long-Sheng, additional, Shen, Chia-Ning, additional, Hsu, Han-Lin, additional, Burnouf, Thierry, additional, Ting, Lai-Lei, additional, Chou, Pai-Chien, additional, Chung, Chi-Li, additional, Lee, Kai-Ling, additional, Shiah, Her-Shyong, additional, Liu, Yen-Lin, additional, and Chen, Yin-Ju, additional

Published
2020
Full Text
View/download PDF

22. Pathology Quiz Case 2

Author

Liao, Li-Jen, Chang, Yih-Leong, Ting, Lai-Lei, and Wang, Cheng-Ping

Published
2006

24. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantative analysis of circulating Epstein-Barr virus DNA

Author

Hong, Ruey-Long, Lin, Chin-Yu, Ting, Lai-Lei, Ko, Jeng-Yuh, and Hsu, Mow-Ming

Subjects
Nasopharyngeal cancer -- Diagnosis, Nasopharyngeal cancer -- Case studies, Nasopharyngeal cancer -- Patient outcomes, Nasopharyngeal cancer -- Care and treatment, DNA -- Analysis, DNA -- Observations, Health
Published
2004

28. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases

Author

Lee Hsin-Lun, Chung Tao-Sang, Ting Lai-Lei, Tsai Jo-Ting, Chen Shang-Wen, Chiou Jeng-Fong, Leung Henry, and Liu H

Subjects
Epidermal growth factor receptor, Non-small cell lung cancer, Brain metastases, Radiotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The presence of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) is associated with increased radiosensitivity in vitro. However, the results from clinical studies regarding the radiosensitivity in NSCLC with mutant EGFR are inconclusive. We retrospectively analyzed our NSCLC patients who had been regularly followed up by imaging studies after irradiation for brain metastases, and investigated the impact of EGFR mutations on radiotherapy (RT). Methods Forty-three patients with brain metastases treated with RT, together with EGFR mutation status, demographics, smoking history, performance status, recursive partitioning analysis (RPA) class, tumor characteristics, and treatment modalities, were included. Radiological images were taken at 1 to 3 months after RT, and 3 to 6 months thereafter. Radiographic response was evaluated by RECIST criteria version 1.1 according to the intracranial images before and after RT. Log-rank test and Cox regression model were used to correlate EGFR mutation status and other clinical features with intracranial radiological progression-free survival (RPFS) and overall survival (OS). Results The median follow-up duration was 15 months. Patients with mutant EGFR had higher response rates to brain RT than those with wild-type EGFR (80% vs. 46%; p = 0.037). Logistic regression analysis showed that EGFR mutation status is the only predictor for treatment response (p = 0.032). The median intracranial RPFS was 18 months (95% CI = 8.33-27.68 months). In Cox regression analysis, mutant EGFR (p = 0.025) and lower RPA class (p = 0.026) were associated with longer intracranial RPFS. EGFR mutation status (p = 0.061) and performance status (p = 0.076) had a trend to predict OS. Conclusions Mutant EGFR in NSCLC patients is an independent prognostic factor for better treatment response and longer intracranial RPFS following RT for brain metastases.

Published
2012
Full Text
View/download PDF

31. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization

Author

Lee, Hsin-Lun, primary, Tsai, Jo-Ting, additional, Chen, Chun-You, additional, Lin, Ying-Chun, additional, Ho, Chin-Beng, additional, Ting, Lai-Lei, additional, Kuo, Chia-Chun, additional, Lai, I-Chun, additional, Lin, Chun-Yu, additional, Tang, Jui-Hsiang, additional, Huang, Yu-Min, additional, Kao, Wei-Yu, additional, Cheng, Sheng-Wei, additional, Shen, Chia-Ning, additional, Chen, Shang-Wen, additional, and Chiou, Jeng-Fong, additional

Published
2019
Full Text
View/download PDF

38. Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer.

Author

Chen, Yin-Ju, Kuo, Chia-Chun, Ting, Lai-Lei, Lu, Long-Sheng, Lu, Ya-Ching, Cheng, Ann-Joy, Lin, Yun-Tien, Chen, Chien-Ho, Tsai, Jo-Ting, and Chiou, Jeng-Fong

Subjects
TREATMENT of oral cancer, CANCER stem cells, CANCER cell migration, CANCER cell proliferation, POLYMERASE chain reaction, EPITHELIUM
Abstract

Piperlongumine (PL), a natural product of Piper longum, inhibits multiple malignant phenotypes. Therefore, the present study examined whether PL suppresses cancer stemness in oral cancer. The cellular effects of PL were determined by examining alterations in tumor sphere formation, cell migration, invasion, proliferation ability, chemosensitivity and radiosensitivity. Reverse transcription-quantitative polymerase chain reaction analysis and western blotting were performed in order to determine molecular expression levels. The present study revealed that PL inhibited cancer stem cell-forming ability and suppressed the expression of the stemness-related transcription factors SRY-Box 2, POU class 5 homeobox 1, and Nanog homeobox. However, it increased the expression of the differentiation marker cytokeratin 18. PL also suppressed cell migration and invasion, resulting in the elimination of the epithelial-mesenchymal transition. Furthermore, PL increased chemo- and radiosensitivity and suppressed tumor growth in vitro and in vivo. The results of the present study suggested that PL inhibits malignant phenotypes via the suppression of cancer stemness in oral cancer. Thus, PL may serve as an effective therapeutic agent for oral cancer. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

42. Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma.

Author

Yaoru Huang, Shang-Wen Chen, Ching-Chao Fan, Lai-Lei Ting, Chia-Chun Kuo, Jeng-Fong Chiou, Huang, Yaoru, Chen, Shang-Wen, Fan, Ching-Chao, Ting, Lai-Lei, Kuo, Chia-Chun, and Chiou, Jeng-Fong

Subjects
LIVER cancer, CHEMOEMBOLIZATION, IRRADIATION, RADIOTHERAPY, PATIENT compliance, THERAPEUTICS, PROGNOSIS, CANCER relapse, HEPATOCELLULAR carcinoma, LIVER, LIVER tumors, RADIATION measurements, RADIATION injuries, PROPORTIONAL hazards models, RETROSPECTIVE studies, KAPLAN-Meier estimator
Abstract

Background: Few data are available on the tolerance of reirradiation in patients with hepatocellular carcinoma (HCC). This study determined the clinical parameters contributing to the development of radiation-induced liver disease (RILD).Methods: We included 36 patients with HCC who received 2 courses of radiotherapy (RT) to the liver. Using α/β = 15 for tumor and α/β =8 for normal liver tissue for biologically equivalent doses in 2 Gy fractions, mean cumulative to the hepatic tumor and normal liver were 87.7 Gy15 and 31.1 Gy8, respectively. Hepatic toxicities were classified according to the Common Terminology Criteria for Adverse Events, Version 4.0. Clinical data, including liver function test results, radiological study findings, and RT parameters before and after both courses of RT were retrieved for analysis. Using multivariate analysis, logistic regression was used to identify the predictors of RILD, and Cox regression was performed to explore the prognostic factors for overall survival (OS).Results: Thirteen patients (36 %) developed RILD after reirradiation. Nine of them died because of progressive liver failure without evidence of tumor progression and were categorized to have lethal RILD. A pretreatment Child-Turcotte-Pugh (CTP) score ≥6 was the only predictor of RILD [odds ratio (OR): 15.83, p = 0.001] and lethal RILD [OR: 72.56, p = 0.005]. In addition, a CTP score ≥6 and the presence of portal vein tumor thrombosis before reirradiation were 2 prognostic factors for OS.Conclusion: Despite a limited sample size, residual liver function using a preirradiation CTP score ≥6 is a clinical parameter associated with an increased risk of RILD in patients requiring hepatic reirradiation. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results